Corporate Banner
Satellite Banner
Technology Networks Header
Thursday, July 24, 2014
Technology Networks
 
Register | Sign in
Home Page>Products
  Product News
Ready-to-Use Lentivirus for miRNA Expression and Inhibition
Saturday, February 01, 2014
AMSBIO’s anti-miRNA lentivirus are produced from the optimally designed anti miRNA lentivectors.

Almac Announces the Presentation of External Validation of ColDx Signature
Friday, January 31, 2014
Data presented supporting Almac developed colon signature as a significant predictor of risk of recurrence in stage II colon cancer.

Massachusetts General Hospital Adopts Advanced Analytical Technology in Fight Against Cancer
Thursday, January 16, 2014
Company's Fragment Analyzer evaluates DNA and RNA of cancer patients.

Affymetrix to Host Workshop on Genomic Selection at PAG Conference
Thursday, January 09, 2014
Plant and animal genome conference at PAG XXII on Monday, January 13 in San Diego.

Compugen to Significantly Expand Immuno-Oncology Activities During 2014
Wednesday, January 08, 2014
R&D expenditures for 2014 anticipated to increase by more than 60%.

ProCure Proton Centers Select RayStation® for Proton Planning
Thursday, December 26, 2013
CE marking and clearance in the US for PBS is expected in early 2014.

Agilent Introduces Two New ScreenTape Assays
Wednesday, December 18, 2013
Two new assays to optimize next-generation sequencing quality control, performance, throughput.

Promega Introduces QuantiFluor ONE dsDNA System
Friday, December 06, 2013
QuantiFluor ONE dsDNA system expands Promega’s nucleic acid quantitation offering.

Cell Therapy Company Uses TAP’s Fill-It Automated Cryovial Processing System
Thursday, December 05, 2013
To rapidly produce consistent cancer immunotherapy batches and cell banks.

<< 4 5 6 7 8 9 10 >>
Showing Results 61 - 70 of 640
Scientific News
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Shenogen and Chemizon Announce Drug Discovery Collaboration Focused on Oncology and Endocrine Disorders
The agreement will create small molecule therapeutics targeting modulators of the ER-alpha 36 receptor.
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv